Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Lupus Nephritis Pipeline 2026: Targeted Therapies and Clinical Innovation Drive New Treatment and Market Opportunities Through the Forecast Period

GlobeNewswire

Dublin, Sept. 24, 2026 -- "Lupus Nephritis - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.

The "Lupus Nephritis - Pipeline Insight, 2026" report delivers a comprehensive analysis of the global lupus nephritis pipeline, covering more than 35 companies and over 42 investigational therapies. It reviews clinical and nonclinical candidates by development stage, product type, route of administration, and molecule type. The report also examines discontinued and inactive products, providing a detailed view of the evolving lupus nephritis treatment landscape.

Lupus Nephritis Overview

Lupus nephritis is a severe renal manifestation of systemic lupus erythematosus and is associated with inflammation, progressive kidney damage, and an elevated risk of end-stage renal disease. Renal involvement frequently occurs within three to five years of systemic lupus erythematosus onset. Monitoring serum creatinine, urine protein-to-creatinine ratios, urinalysis findings, complement levels, and anti-double-stranded DNA antibodies is central to early detection and disease management.

Clinical presentation may include hypertension, edema, unexplained weight gain, proteinuria, hematuria, foamy urine, and increased nighttime urination. Renal lesions can affect the glomerular, tubulointerstitial, and vascular compartments. Immune-complex deposition in mesangial, subendothelial, and subepithelial regions contributes to complement activation, inflammatory-cell recruitment, and renal injury.

Renal biopsy remains essential for confirming lupus nephritis, determining histological class, assessing disease activity and chronicity, and guiding treatment decisions. Management is based on disease severity and classification. Hydroxychloroquine is commonly used as baseline therapy unless contraindicated. Proliferative disease generally requires induction therapy with mycophenolate mofetil or cyclophosphamide in combination with glucocorticoids, followed by maintenance immunosuppression to preserve renal response and reduce relapse risk.

Report Scope and Market Intelligence

The report combines disease analysis, treatment guidelines, commercial assessment, and clinical evaluation of lupus nephritis pipeline products. Individual drug profiles include mechanisms of action, clinical study information, regulatory developments, technology platforms, product designations, and development status. The analysis also covers licensing agreements, collaborations, funding, mergers, acquisitions, and other strategic activities influencing lupus nephritis research and development.

Companies and academic organizations are pursuing novel approaches intended to improve renal response, reduce treatment resistance, limit relapse, and address the toxicity associated with long-term immunosuppression. Development programs span targeted antibodies, complement inhibitors, small molecules, engineered cellular therapies, recombinant fusion proteins, peptides, polymers, and gene therapies.

Selected Emerging Lupus Nephritis Drugs

  • Ianalumab - Novartis: Ianalumab, also known as VAY736, is an investigational fully human monoclonal antibody targeting the BAFF receptor. Its mechanism combines antibody-dependent cellular cytotoxicity-mediated B-cell depletion with inhibition of B-cell survival signaling. The candidate is being evaluated in Phase III development for lupus nephritis.
  • HSK39297 - Haisco Pharmaceutical Group Co., Ltd.: HSK39297 is an oral, selective Factor B inhibitor targeting the alternative complement pathway. The program is designed to suppress amplification of complement-mediated inflammatory activity and reduce renal C3 deposition. It is currently in Phase II development for lupus nephritis.
  • CNTY-101 - Century Therapeutics, Inc.: CNTY-101 is an investigational allogeneic, induced pluripotent stem cell-derived natural killer cell therapy featuring a CD19-directed chimeric antigen receptor, Allo-EvasionT edits, and IL-15 expression. The candidate is undergoing Phase I evaluation for lupus nephritis.

Therapeutic and Pipeline Assessment

The lupus nephritis pipeline report evaluates late-stage, mid-stage, early-stage, preclinical, discovery, discontinued, and inactive candidates. Novartis is among the companies with a program in Phase III development, while numerous biotechnology and pharmaceutical organizations are advancing therapies across Phase II, Phase I, and nonclinical stages.

Pipeline products are assessed across oral, intravenous, subcutaneous, parenteral, and topical routes of administration. Molecule categories include monoclonal antibodies, small molecules, recombinant fusion proteins, peptides, polymers, and gene therapies. Products are also categorized as monotherapies, combination therapies, or candidates with potential use in both settings.

Key Report Insights

  • Analysis of more than 42 lupus nephritis pipeline products
  • Profiles of more than 35 companies active in lupus nephritis drug development
  • Clinical, commercial, and therapeutic assessment of emerging candidates
  • Evaluation of unmet needs and the potential impact of investigational therapies
  • Review of clinical trials, regulatory designations, and product development milestones
  • Assessment of collaborations, licensing transactions, mergers, acquisitions, and funding activities
  • Coverage of inactive and discontinued lupus nephritis programs

Key Pipeline Products

Featured lupus nephritis pipeline candidates include Ianalumab, HSK39297, CNTY101, HB2198, SYNCAR-001, AB-101, CTX112, CRC01, C-CAR168, CABA-201, KYV-101, ICG318, NKX019, HLX79, and Povetacicept.

Strategic Questions Addressed

  • How many companies and pipeline products are active in lupus nephritis development?
  • Which therapies have reached mid-stage and late-stage clinical development?
  • What clinical studies are underway, and what is their current status?
  • Which novel mechanisms and technologies may address limitations of existing treatments?
  • What collaborations, licensing agreements, mergers, and acquisitions are shaping the market?
  • Which regulatory designations have been granted to emerging lupus nephritis therapies?

The "Lupus Nephritis - Pipeline Insight, 2026" report provides stakeholders with a focused resource for evaluating emerging therapies, competitive positioning, research trends, clinical progress, and strategic opportunities across the global lupus nephritis drug development landscape.

A selection of companies mentioned in this report includes, but is not limited to:

  • Novartis
  • Haisco Pharmaceutical Group Co., Ltd.
  • Century Therapeutics, Inc.
  • Hinge Bio
  • Synthekine
  • Artiva Biotherapeutics, Inc.
  • CRISPR Therapeutics
  • Curocell Inc.
  • AbelZeta Inc.
  • Cabaletta Bio
  • Kyverna Therapeutics
  • iCell Gene Therapeutics
  • Nkarta, Inc.
  • Fosun Pharma
  • Vertex Pharmaceuticals

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/5k2stk

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. Stallion Power Gummies Releases 2026 Ingredient, Usage and Safety Details for Its Male Enhancement Formula in the US and CanadaStallion Power Male Enhancement Gummies Combine Muira Puama, Maca Root, Horny Goat Weed, L-Arginine, Tribulus Terrestris, Catuaba, Ashwagandha, Green Tea Extract and Caffeine in a Once-Daily Gummy for Adult Men
  2. CryptoU-topia Launches Public Beta as Global Builders Gather for U-HackathonFinancial technology company opens its app in more than 50 countries during FLOW Summit as 500-plus builders develop AI and Web3 products
  3. FinanceROSEN, SKILLED INVESTOR RIGHTS COUNSEL, Encourages AST SpaceMobile, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ASTSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AST SpaceMobile, Inc. (NASDAQ: ASTS) between March 4, 2025 and July 15, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline.
  4. FinanceROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Baidu, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIDUWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baidu, Inc. (NASDAQ: BIDU) between November 18, 2025 and August 17, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline.
  5. FinanceBBNX DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNXWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the “Class Period”), of the important November 3, 2026 lead plaintiff deadline.
  6. FinanceROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TYGOWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tigo Energy, Inc. (NASDAQ: TYGO) between February 24, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), of the important November 23, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.